<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="206161">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404755</url>
  </required_header>
  <id_info>
    <org_study_id>#5294R</org_study_id>
    <secondary_id>IRB 5294R</secondary_id>
    <nct_id>NCT00404755</nct_id>
  </id_info>
  <brief_title>Dichotic Listening as a Predictor of Medication Response in Depression</brief_title>
  <official_title>Dichotic Listening as a Predictor of Medication Response in Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will recruit 100 depressed patients to test whether the previous finding of an
      association between treatment response (with treatment groups including placebo, imipramine,
      and fluoxetine) and preferences of hemispheric laterality in perceptual processing are also
      found with a different type of commonly used anti-depressant, bupropion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary data suggest that depressed patients with increased left hemispheric laterality
      of perceptual processing are unlikely to improve during 6 weeks' treatment with placebo,
      while being very responsive to either imipramine or fluoxetine. Depressed patients who do
      not show evidence of poor right hemispheric functioning respond significantly more often to
      placebo than those with poor right hemispheric functioning , and do not show an advantage of
      drug over placebo. 100 patients will be tested with verbal and nonverbal dichotic tests, and
      then treated sequentially with bupropion, escitalopram, and imipramine. Preferential
      hemisphere for auditory processing will be correlated with treatment outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Scale (HAM-D); Fuse Words Test; Nonsense Syllables Test; Complex Tones Test</measure>
    <time_frame>6 mos.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale (CGI); Atypical Depression Diagnostic Scale (ADDS); Derogotis Sexual Performance Scale; Snaith-Hamilton Pleasure Scale; Spielberger State/Trait Anxiety Scale</measure>
    <time_frame>6 mos.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Dysthymia</condition>
  <arm_group>
    <arm_group_label>escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escitalopram 10 mg/d for 1 week, then increasing by 10 mg/week if tolerated and not remitted to maximal dose of 40 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bupropion XL 150 mg/d for a week, then 300 mg/d for a week and then 450 mg/d; all dose increases if tolerated and not remitted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>imipramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then by 50 mg/week to a maximum dose of 300 mg/d; all dose increases if tolerated and not remitted</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d</description>
    <arm_group_label>escitalopram</arm_group_label>
    <other_name>Lexapro.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion</intervention_name>
    <description>bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d</description>
    <arm_group_label>bupropion</arm_group_label>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imipramine</intervention_name>
    <description>imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted</description>
    <arm_group_label>imipramine</arm_group_label>
    <other_name>Tofranil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages between 18-65

          2. Meets DSM-IV criteria for current Major Depression, Dysthymia or Depression NOS

        Exclusion Criteria:

          1. Known Hearing impairment

          2. Active suicidal ideation (history of suicide attempts will be evaluated on a case by
             case basis).

          3. HAMD&gt;20

          4. Current (past 6 months)alcohol and/or drug abuse or dependence

          5. Medical condition likely to require intervention contraindicated with study
             medication (e.g., known arrhythmia likely to be exacerbated by Imipramine)

          6. Bipolar I

          7. Psychosis

          8. Non-response to adequate trial of study medication (i.e., &gt; or = 4 weeks on &gt; or =
             bupropion 300mg/d, escitalopram 30mg/d, or imipramine 200mg/d)

          9. Premenopausal women not using known effective birth control

         10. Not currently depressed (whether considered due to current treatment or not)

         11. History of seizure, seizure disorder, anorexia nervosa, or bulimia

         12. Left-handed -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan W. Stewart, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerard Bruder, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.depression-nyc.org</url>
    <description>Depression Evaluation Service official website</description>
  </link>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 26, 2012</lastchanged_date>
  <firstreceived_date>November 28, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Imipramine</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
